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Available online 25 August 2019Background: Targeting of MDSCs is a major clinical challenge in the era of immunotherapy. Antibodies which de-
plete MDSCs in murine models can reactivate T cell responses. In humans such approaches have not developed
due to difﬁculties in identifying targets amenable to clinical translation.
Methods: RNA-sequencing ofM-MDSCs and G-MDSCs from cancer patients was undertaken. Flow cytometry and
immunohistochemistry of blood and tumours determined MDSC CD33 expression. MDSCs were treated with
Gemtuzumab ozogamicin and internalisation kinetics, and cell death mechanisms determined by ﬂow cytome-
try, confocal microscopy and electron microscopy. Effects on T cell proliferation and CAR-T cell anti-tumour cy-
totoxicity were identiﬁed in the presence of Gemtuzumab ozogamicin.
Findings: RNA-sequencing of humanM-MDSCs andG-MDSCs identiﬁed transcriptomic differences, but that CD33
is a common surface marker. Flow cytometry indicated CD33 expression is higher on M-MDSCs, and CD33+
MDSCs are found in the blood and tumours regardless of cancer subtype. Treatment of human MDSCs leads to
Gemtuzumab ozogamicin internalisation, increased p-ATM, and cell death; restoring T cell proliferation. Anti-
GD2-/mesothelin-/EGFRvIII-CAR-T cell activity is enhanced in combination with the anti-MDSC effects of
Gemtuzumab ozogamicin.
Interpretation: The study identiﬁes that M-MDSCs and G-MDSCs are transcriptomically different but CD33 is a
therapeutic target on peripheral and inﬁltrating MDSCs across cancer subtypes. The immunotoxin Gemtuzumab
ozogamicin can deplete MDSCs providing a translational approach to reactivate T cell and CAR-T cell responses
against multiple cancers. In the rare conditions of HLH/MAS gemtuzumab ozogamicin provides a novel anti-
myeloid strategy.
Fund: Thisworkwas supported by Cancer Research UK, CCLG, Treating Childrenwith Cancer, and the alumni and
donors to the University of Birmingham.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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CAR-T1. Introduction
Cancer cells exist within an immune microenvironment, containing
populations of cells which can coordinate and target the cancer or in
contrast be subverted to promote cancer growth and survival [1].
Approaches to boost autologous T cell activity or engineer T cell immu-
notherapies have seen somedramatic clinical responses [2]. However inImmunotherapy, University of
. This is an open access article undersolid cancer and non-B-cell haematological malignancy trials clinical re-
sponses are disappointing, with poor Chimeric-Antigen Receptor T cell
(CAR-T) expansion and persistence short-lived [3–5]. The failure is
mainly due to an immunosuppressive microenvironment mainly cre-
ated by Myeloid-Derived Suppressor Cells (MDSCs) in the tumours
and blood of patients [6,7]. MDSCs may suppress T cell activity through
diverse mechanisms including expression of immune checkpoint sur-
face molecules, release of nitric oxide or reactive oxide species, produc-
tion of immunomodulatory cytokines, or the consumption of amino
acids [6–9]. Myeloid cells also play critical roles in driving other dis-
eases. Haemophagocytic Lymphohistiocytosis (HLH) and Macrophage
Activation Syndrome (MAS) are a spectrum of rare conditions which
may be familial or secondary to cancer, infection, or autoimmunity.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Research in Context
Evidence before this study
Depletion ofMyeloid-Derived Suppressor Cells (MDSCs), with un-
conjugated antibodies, in murine cancer models suggests that T
cell responses can be reactivated against cancer. In humans,
small molecule inhibitors which modulate MDSC intracellular sup-
pressive mechanisms, have been trialled but have not shown the
capacity to deplete MDSCs and restore T cell responses consis-
tently across cancer groups.
Added value of this study
We identified that although human M-MDSCs and G-MDSCs are
transcriptomically distinct, CD33 expression provides a surface
target for both circulating and intra-tumoural MDSCs across can-
cer subtypes. Targeting of MDSCs with the anti-CD33
immunotoxin Gemtuzumab ozogamicin leads to immunotoxin
internalisation, increased p-ATM, andMDSCcell death. The result
is restoration of T cell proliferation and enhanced CAR-T cell prolif-
eration and cytotoxicity against solid cancer targets.
Implications of all the available evidence
Our study suggests that Gemtuzumab ozogamicin provides the
clinically relevant approach to deplete MDSCs in cancer patients,
or pathologicalmyeloid cells inHLH/MAS, and could overcome im-
munosuppressivemicroenvironments to reactivate T cell immuno-
therapy. These findings will be translated into a Phase II clinical
trial (GOTHAM).
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tion and severe, life-threatening systemic inﬂammation marked by
fever, high ferritin and hypertriglcyeridemia [10,11]. Expansions of my-
eloid cells which secrete pro-inﬂammatory factors such as IL-6, Il-18,
and Il-1β is central to the underlying pathology, yet to date no therapies
have directly targeted these cells contributing to a high mortality [12].
In murine models monocytic MDSCs can be readily deﬁned by their
expression of surface antigens such as Ly6C or CCR2 [13]. Administra-
tion of targeted antibodies that speciﬁcally deplete murine MDSCs, re-
sults in reactivation of anti-cancer T cell responses and tumour
resolution – proof of principle that antibody targeting of these cells
can have a dramatic and helpful effect on immunity [14]. Although
markers for human MDSCs have been identiﬁed, such as CD10 or
LOX1, expression is subtype-speciﬁc and clinical agents against these
molecules are not well developed [15,16]. Furthermore clinical ap-
proaches to remove human MDSCs have been limited by complexities
of MDSC characterisation, poor correlation between murine models
and patients, and their ability to suppress T cells through multiple
mechanisms [17]. One of the most clinically successful methods for se-
lective cell depletion is the use of immunotoxins – antibody-toxin con-
jugates which induce cell-speciﬁc death [18]. Here we investigate
potential clinically relevant targets for depleting MDSCs to reactivate
T cell immunity.2. Methods
2.1. Patient samples
Heparinized blood samples were obtained from adult patients with
cancers of the lung (n= 21), pancreas (n = 7), colon (n= 36), brain
(n = 7), head and neck (n = 8), prostate (n = 10), breast (n = 12),melanoma (n=5) and paediatric patients withWilms' (n= 5), neuro-
blastoma (n=31), Ewing's (n=2), non-Hodgkin's lymphoma (n=2),
rhabdomyosarcoma (n=2) at diagnosis, prior to treatment. Blood from
healthy donors (n=41)was obtained at the University of Birmingham,
UK. Healthy leukocyte cones were provided by the NHSBT Blood Bank
(Birmingham, UK).
2.2. Study approvals
In accordancewith the Declaration of Helsinki, patient sampleswere
obtained after written, informed consent prior to inclusion in the study.
Adult patient samples were collected through the University of
Birmingham's Human Biomaterials Resource Centre (HBRC, Birming-
ham, UK). HBRC is licensed by the Human Tissue Authority to collect
process and store project-independent human samples for biomedical
research. Samples collected byHBRC are released under Research Tissue
Bank ethical approval by the North West Research Ethics Committee,
Haydock Park (Ref 15/NW/0079). Samples from Birmingham Children's
Hospital were collected following Regional Ethics Committee (REC
Number 10/H0501/39) approval.
2.3. Flow cytometric analysis of whole blood
All samples were processed within 12 h from collection. Whole
blood was lysed prior to staining using the RBC Lysis solution (Qiagen,
Germany) according to manufacturer's speciﬁcation. Immune popula-
tions were identiﬁed by staining with ﬂuorophore-conjugated anti-
CD11b, anti-CD33, anti-CD3, anti-HLA-DR, anti-CD45, anti-CD68, anti-
CD206, anti-CD163, (BioLegend), anti-CD14, anti-CD15 (eBioscience)
antibodies on ice for 30 min. Fluorescence data was acquired using BD
Accuri C6 (BD Biosciences), Cyan and/or CytoFLEX (Beckman Coulter)
cytometers. Normalised population statistics –including the median
ﬂuorescence intensities (MFI) were determined using FlowJo (BD Bio-
sciences, formerly developed by FlowJo LLC).
Where indicated cell death was assessed by propidium iodide stain-
ing of cells after 72 h incubation with Gemtuzumab ozogamicin (Gift
from Pﬁzer).
2.4. Myeloid cell and lymphocyte isolation
Where indicated myeloid cells were isolated from peripheral blood
using a Lymphoprep gradient (STEMCELL Technologies) and enriched
from the white cell layer by positive magnetic assisted cell sorting
(MACS) using anti-human CD14 Microbeads (Miltenyi Biotech) and
MACS LS separation columns (Miltenyi Biotech). T-lymphocytes were
obtained by negative selection after removal of myeloid cells. Cell
purities of each distinct population of N98% was conﬁrmed after isola-
tion by ﬂow cytometry using ﬂuorophore-conjugated anti-CD14 or
anti-CD3 antibodies.
2.5. RNA-sequencing
MDSCs were isolated from the peripheral blood of prostate,
lung, head and neck, breast, andmelanoma cancer patients at diagnosis
(n=3per cancer) according to consensus guidelines usingﬂow cytom-
etry immunophenotyping and T cell proliferation assays as above [13].
RNA was derived from the MACS bead sorted CD14+ M-MDSCs and
CD15+G-MDSCs from cancer patients at diagnosis. Purity was checked
by ﬂow cytometry. Samples were prepared with the Illumina TruSeq
RNA Sample Preparation Kit v2. They were sequenced on the Illumina
HiSeq2000 platform using TruSeq v3 chemistry, over 76 cycles.
Sequencing reads were aligned to GRCh37 human genome using STAR
RNA-Seq aligner software [19]. Reads mapping to transcripts were
counted by the same software. Normalisation of read counts and differ-
ential expression analysis comparing M-MDSCs and G-MDSCs was
performed using DESeq2 R Bioconductor package [20].
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A tissue micro-arrays (TMA) of 200 human tumours (n= 40 cases
each of non-small cell lung carcinoma, prostate adenocarcinoma, breast
invasive ductal carcinoma, colon adenocarcinoma, and pancreas duct
adenocarcinoma) and normal control tissues (US Biomax) were
deparafﬁnised and rehydrated following quality control to conﬁrm di-
agnosis and antigen preservation. Tumours were stained on a Ventana
Discovery Ultra automated system, according to manufacturer's proto-
col. Heat-induced antigen retrieval was performed with cell condition-
ing 1 buffer (CC1), pH 8.5 (Ventana). Protein blocking was applied
with Background Sniper (Biocare Medical, Concord, CA). Staining with
anti-human CD33 (Abcam)was performed at 37 °C, followed by the ad-
dition of secondary antibodies (Discovery anti-Rabbit HQ) using the
Novolink Polymer Detection System (RE7280-K, Leica). Primary anti-
body incubation were carried out overnight at 4 °C and tissue sections
were counterstained with haematoxylin and mounted in DPX (VWR).
To assess nonspeciﬁc staining, samples were similarly treated but the
primary antibodies omitted and replacedwith isotype speciﬁc IgG (Vec-
tor Labs Peterborough UK).
Parafﬁn-embedded tissue sections of bonemarrow trephines from 8
cancer-associated HLH patients at diagnosis were deparafﬁnised and
rehydrated. Antigen retrieval was performed in 50 mM Tris/2 mM
EDTA pH 9.0 using a Philips Whirlpool Sixth Sense microwave on a
steaming program. Staining with anti-human CD33 (Abcam) was per-
formed using the Novolink Polymer Detection System (RE7280-K,
Leica). Primary antibody incubation was performed overnight in a
cold room. Sections were counterstained with Gill Nr 3 haematoxylin
(Sigma Aldrich) and mounted in Aquatex (Merck).
Antigen expression in immunohistochemistry sections were
assigned independently by experienced pathologists. Brieﬂy, to evalu-
ate the immunostaining intensity in the tumour and bone marrow
stroma each slide was examined on an Olympus BX51 microscope.
Representative 400× magniﬁcation ﬁelds of at least 100 tumour cells
were selected andphotographedwith anOlympusDP70 camera and ac-
companying image software. Fields were assigned an antigen staining
intensity score of 0 = negative, + = weak, ++ = moderate, +++
= strong.
2.7. Gemtuzumab ozogamicin
MDSCs were seeded in complete medium at a density of 1 × 106
cells/well of a 12 well plate. Unless otherwise stated, Gemtuzumab
Ozogamicin (GO, Pﬁzer)was added at a concentration of 1 μg/ml and in-
cubated for 48 h at 37 °C and 5% CO2. Analysis of cell death was moni-
tored via propidium iodide (PI) (Sigma) uptake quantiﬁed on the
CyTOFLEX ﬂow cytometer. The cytotoxicity of unconjugated
gemtuzumab antibody (AbsoluteAntibody) (2 μg/ml) and gemtuzumab
ozogamicin (2 μg/ml) was similarly compared. For drug internalisation
assays, GO was covalently labelled to AlexaFluor-647 ﬂuorophore,
with the Alexa Fluor Protein Labeling Kit (Life Technologies, Carlsbad,
USA) as per the manufacturer's instructions. 1 μg/ml of labelled GO
was added to cells and incubated on ice for 30 min to allow binding to
the CD33 receptor, then at 37 °C at different time points for
internalisation. Membrane-bound non-internalised drug was stripped
using stripping buffer (0.2MGlycine HCl, pH 2.2) and the cells analysed
by ﬂow cytometry. The MFIs of AlexaFluor-647 was determined using
FlowJo (BD Biosciences, formerly developed by FlowJo LLC).
2.8. T lymphocyte proliferation assay
2 × 10 [5]/well of T cells were cultured in 96-well ﬂat bottom plates
coated with anti-CD3 (OKT3) antibody (3 μg/mL) and anti-CD28 anti-
body (2 μg/mL) (both eBioscience), in 200 μL R10% supplemented
with 0.1% β-mercaptoethanol (Thermo Fisher Scientiﬁc). Cells were
for 4 days incubated at 37 °C, 5% CO2 and their proliferation determinedby 3H-thymidine (Perkin Elmer Life Sciences) incorporation assay using
a TopCount NXT Scintillation Counter (Perkin Elmer). The suppressive
ability of GO treated or untreated MDSCs was determined by direct
co-culture with T cells. The data is expressed as a percentage of T cell
proliferation driven by antibody stimulation in the presence of MDSCs
relative to T cell proliferation in their absence (100%).
2.9. ELISA
The concentrations of cytokineswithin the patient's plasmas at diag-
nosis, were quantiﬁed using a competitive enzyme-linked immunoas-
say according to the manufacturers' instructions. The following
molecules were tested: G-CSF, TGFβ, VEGF (all R&D Systems), IL-10,
IL-4, IL-13, IL-6, IL-15, GM-CSF (all BioLegend).
2.10. Transmission electron microscopy
GO-treated, patient-derived MDSCs were pelleted at a density of 1.5
× 106 cells/tube, ﬁxed in 2.5% glutaraldehyde and stained with 1% os-
mium tetroxide. The samples were dehydrated using ethanol and
ﬁxed in amixture of propylene oxide and resin at 60 °C for 16 h. Sections
of 80 nm thick resin and sample were then taken and embedded onto
copper slot grids for visualization under transmission electron micros-
copy (TEM).
2.11. Cell lines
Ewing sarcoma cell line (SKNMC), neuroblastoma cell lines (SKNAS,
KELLY, IMR-32 and LAN-1) andmesothelin positive lung cancer cell line
(H1299M) were routinely cultured in RPMI 1640 medium. Colorectal
cell lines (Caco-2, SW480), caecal adenocarcinoma cell line (SNUC5),
the pancreatic carcinoma cell line of ductal cell origin (PANC1) were
cultured in DMEM (Sigma). All cell line media was supplemented with
10% v/v fetal bovine serum (FBS, Sigma), 100 U/mL penicillin and strep-
tomycin (Gibco), 1 mmol/l- sodium pyruvate (Gibco), and 2 mmol/l L-
glutamine (Gibco). Cell lines were originally obtained from ATCC and
validated for authenticity by DNA short tandem repeats in line with
American National Standards Institute ASN-0002-2011 (Northgene).
Culture supernatants were harvested 72 h later from cultureﬂaskmain-
tained in an incubator at 5% CO2 in air and at 37 °C. To generate tumour-
polarised MDSCs, healthy CD14+ cells from leukocyte cones were cul-
tured for 48 h in tumour-conditioned supernatant as previously
described [7].
2.12. Immunoﬂuorescence
MDSCs were seeded unto sterile No.1 (13 mm diameter) glass
coverslip-inserts (VWR) at 1 × 104 perwell of a 24-well plate andmain-
tained overnight at routine culture or experimental conditions. Cells
were stained with anti-CD33 PE, washed in ice-cold PBS, ﬁxed in 2%
Paraformaldehyde for 20 min at RTP followed by permeabilisation in
0.1% Triton X for 10min. After permeabilisation coverslips were blocked
in a blocking buffer consisting of 5% heat inactivated goat serum
(HiNGS) in PBS for 1 h at RTP. Coverslips were then incubated for 1 h
with an eFluor 660 conjugated anti human Phospho-ATM(Ser1981) an-
tibody (Clone 10H11.E12 3G5, eBiosciences) diluted 1:100 in 5%HiNGS/
PBS. The coverslips were washed air dried, then mounted in SlowFade
gold antifade mountant with DAPI (ThermoFisher Scientiﬁc). Cells
were examined by ﬂuorescence microscopy using a Zeiss LSM 780 ﬂuo-
rescence confocal microscope and images acquired using ZEN software
suite (Carl Zeiss Microscopy).
2.13. CAR-T cell functional assays
T cells were engineered to express chimeric antigen receptors (CAR)
for Mesothelin, GD2 and EFGRvIII based on established protocols
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Mesothelin, anti-EGFRvIII and anti-GD2 CAR-containing retroviruses
48 h post-stimulation with anti-CD3/CD28. Successfully transduced T
cells were FACS sorted exploiting the truncated-CD34 tag added to the
construct and purity was checked by ﬂow cytometry.
Tumour cell expression of target antigenswas conﬁrmed by ﬂow cy-
tometry using antibodies against mesothelin (Santa Cruz) and GD2
(Biolegend). For EGFRvIII, glioma cells were ﬁrst dissociated from
fresh human tumourswithin 24 h of surgery. RT-PCRwas used to detect
EGFRvIII expression. RNA was extracted using an RNeasy Mini kit
(Qiagen). cDNA was prepared using SuperScriptTM III Reverse Tran-
scriptase (Invitrogen) following the manufacturer's instructions. The
PCRproducts were analysed by gel electrophoresis on a 2% agarose gel
and were visualised by staining with ethidium bromide. The primer se-
quences are as follows: Primer 1 (Forward: 5′-ATGCGACCCTCCGGGA
CG-3′ Reverse: 5′-ATTCCGTTACACACTTTGCGGC -3′) and Primer 2 (For-
ward: 5′-GAGCTCTTCGGGGAGCAG-3′ Reverse: 5′-GTGATCTGTCACCA
CATAATTACCTTTTCT-3′) [23,24].
For the chromium assays, CAR T cells were incubated with antigen-
positive tumour cells and antigen-negative controls, at 100:1, 33:1,
11:1, and 3:1 ratios in a 4-h 51Cr-release assay [22]. CAR-T cells were
subsequently co-cultured with CFSE-labelled target-bearing cells (i.e.
anti-Mesothelin with H1299M, anti-EGFRvIII with tumour cells isolated
from glioma brain tumours, anti-GD2 with LAN-1), in presence of GO-
treated or untreated MDSCs. Viability and number of tumour and
CAR-T cells were investigated by ﬂow cytometry using PI staining.
2.14. Statistical analysis
Parametric student t-tests were used to determine the statistical sig-
niﬁcance of the difference in paired observations between groups
(GraphPad Prism, USA). All p values are two-tailed and p values b.05
were considered to represent statistically signiﬁcant events.
3. Results
To identify a MDSC surface target amenable for immunotoxin
targeting CD14+ monocytic (M-MDSC) and CD15+ granulocytic (G-
MDSC) MDSCs were isolated by immunophenotype and suppressive
ability, according to consensus guidelines, from patients with different
cancers (Fig. 1A and B) [13]. Generation of a RNA-sequencing library,
to identify potential drug targets, revealed signiﬁcant differences in
the transcriptomic proﬁles of M-MDSCs and G-MDSCs (Fig. 1C and D).
Analysis of the top 300 differentially expressed genes identiﬁed 3 po-
tential targets for existing immunotoxins – CD74 [25], CD86 [26], and
CD33 [27]. Of these, CD33 is the only one which clinically advanced in
human trials. CD33 is a transmembrane Sialic-Acid-Binding-
immunoglobulin-like lectin (SIGLEC) composed of a type 1 membrane
proteinwith two immunoglobulin domains that binds sialic acid and in-
tracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs)
[28]. Knockout of the murine CD33 ortholog has no phenotype or role
in deﬁning murine MDSC populations [29]. Human CD33 on Acute My-
eloid Leukaemia blasts has been successfully targeted by Gemtuzumab
ozogamicin (GO), an anti-CD33 humanized antibody conjugated to
calicheamicin in Phase III clinical trials [27]. We hypothesised that
humanMDSC CD33 could similarly be targeted, as a strategy across can-
cer subtypes.
Examination of 200 patient samples revealed signiﬁcant inﬁltrations
of CD33+myeloid cells in the tumour stroma compared to healthy tis-
sues (Fig. 2A,B and Supp 1A,B).More rarely abnormal expansion and ac-
tivation of myeloid cells can lead to a severe and life-threatening
systemic inﬂammation - Haemophagocytic Lympho-Histiocytosis
(HLH) or a Macrophage Activation Syndrome (MAS). In these rare pa-
tients we also identiﬁed a high frequency of CD33+ cells in bone mar-
row staining (Fig. 2C, Supp Fig. 2). The majority of cancer or HLH
samples had high intensity of CD33 positivity (Fig. 3A and B). In theblood, CD33 intensity was greater on the M-MDSCs compared G-
MDSCs (Fig. 3C) and this population is expanded compared to healthy
controls (Fig. 3D). Culture of sorted CD33+MDSCs conﬁrmed their abil-
ity to suppress T cell proliferation (Fig. 3E), consistent with a reduction
in peripheral T cells observed in patients at diagnosis (Supp Fig. 3A). No-
tably CD33+ cells sorted from the blood of healthy donorswere not im-
munosuppressive. Thus CD33 is expressed on theMDSCs pathologically
expanded in the blood and tumour tissues of adults and children with
cancer and which create an immunosuppressive microenvironment.
Incubation of CD33+ MDSCs from cancer patients with ALEXA647
labelled-GO conﬁrmed binding predominantly to the M-MDSC popula-
tion (Supp Fig. 3B), and rapid immunotoxin internalisation (Fig. 4A and
Supp Fig. 3C). Although the unconjugated gemtuzumab antibody had
minimal effect on survival (Supp Fig. 3D), Gemtuzumab ozogamcicin in-
duced a dose-dependent decrease in viability (Fig. 4B, C, Sup Fig. 3D and
4A) of M-MDSCs from patients' PBMCs or tumour-polarised CD33+
myeloid cells (Fig. 4D), with no effect on CD33- cells. Suppressive tu-
mour polarised CD33+ cells (Supp Fig. 4C) down-regulated HLA-DR
and upregulated CD68 consistent with a M1-like phenotype (Supp
Fig. 4D). GO treatment leads to increased pATM (Fig. 4E, Supp Fig. 5A)
consistent with calicheamicin induced DNA-damage [30]. Electron mi-
croscopy revealed a loss of cell membrane integrity, nuclear condensa-
tion, and blebbing marking apoptotic cell death (Fig. 4F and Supp
Fig. 5B).
Treatment of circulating or tumour-polarised MDSCs, with GO, re-
stores T cell proliferation (Fig. 5A). The ﬁnding has potential clinical im-
portance for CAR-T therapies against solid tumours, where CAR-T cell
numbers in the blood and tumours fall rapidly post-infusion, despite
the presence of target antigens. We hypothesised that circulating im-
munosuppressive cytokines from tumours could limit CAR-T expansion
and anti-tumour activity. Howeverwith the exception of TGF-β [31], we
found no consistent signiﬁcant increases in IL-10, IL-4, Il-13, Il-6, GM-
CSF, G-CSF, or VEGF in the blood that could account for the failure across
cancer patients (Supp Fig. 6A-F). Instead systemic and intra-tumoural
MDSCs may play a more prevalent pan-tumour inhibitory role [32].
CAR-T cells against 3 of the most common antigen targets were gener-
ated (Supp Fig. 6G) –Mesothelin, GD2 and EGFRvIII (Supp Fig. 7A, B,C).
Antigen-speciﬁcity of CAR-T cell killing against corresponding tumour
cell targets was ﬁrst conﬁrmed (Supp Fig. 7D,E,F). Mimicking patients'
ﬁndings, MDSCs suppressed CAR-T cell proliferation, irrespective of
the scFv, but this was overcome by GO-treatment(Fig. 5B,C). MDSCs
also impaired CAR-T cell cytotoxicity. However GO-killing of MDSCs im-
proved the effectiveness of each CAR-T construct, leading to a further
signiﬁcant reduction in viable mesothelioma and, neuroblastoma cells
(Fig. 5D,E). Thus GO can kill MDSCs, overcome the immunosuppressive
microenvironment, and provide a therapeutic boost to CAR-T cell activ-
ity (Fig. 6).
4. Discussion
The resurgence in T cell immunotherapy approaches for adult and
paediatric cancers has highlighted the need for clinically relevant strat-
egies against the underlying immunosuppressive microenvironment.
One of the major mechanisms of tumour-immune escape, is through
the expansion of immunosuppressive MDSCs [33]. It is well established
that these cells may be signiﬁcantly increased in the blood and tumours
of adults and children with solid malignancies regardless of tumour
type, and are associated with higher stage, metastatic disease, and a
worse prognosis. These cells have been polarised by the tumour micro-
environment to switch off autologous anti-cancer T cells responses and
can impair both the manufacturing and efﬁcacy of CAR-T cells
[21,22,32].
One of the principle challenges in targeting human MDSCs remains
their heterogeneous nature, with differences in immunophenotype
and intracellular mechanisms of suppression both within the same pa-
tient (blood vs tumoural) and across different types of cancer diagnoses.
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Fig. 2. CD33+ MDSC inﬁltration in the tumours and bone marrow of cancer and HLH patients. A) Immunohistochemical analysis of tissue microarray (n = 200 cancer patients)
B) Photomicrographs of representative CD33+ immunohistochemistry staining within lung, prostate, colon, pancreas, and breast tumours within the TMA (upper panels) and normal
healthy control tissues (lower panels) C) Representative immunohistochemical staining of sections from bone marrows of HLH patients (n= 8) showing inﬁltration of CD33+ MDSCs.
240 L. Fultang et al. / EBioMedicine 47 (2019) 235–246Murine MDSCs can be readily characterised by immunophenotype,
which has allowed for a detailed study of suppressive pathways and in-
deed transcriptomic changes [34,35]. However humanMDSCs require a
multi-step approach with relatively crude techniques including density
centrifugation. To help identify new targets for clinical translation we
generated a RNA-sequencing library from both M-MDSCs and G-
MDSCs, to our knowledge the ﬁrst such attempt at this strategy. It re-
veals clear separation of the MDSC at the transcriptomic level,
conﬁrming that these populations are indeed distinct. Although wefocused on screening the library for potential clinical targets to deplete
MDSCs, we suggest such data will also allow for an improved under-
standing of the underlying biology of M-MDSCs and G-MDSCs and
could identify other strategies to isolate or modulate these cells.
Here we have identiﬁed how CD33 marks the MDSCs which are
found in the blood and tissues of patients across cancers. Binding of si-
alic acid ligands to CD33 can induce a number of physiological function
resulting in inhibition of cellular proliferation and activation, apoptosis,
or modulation of cytokine release [36]. However Siglecs, such as CD22,
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Fig. 3.CD33expression characterises theMDSCpopulation in the tumours and blood of cancer patients. A) Intensity of CD33+staining onMDSCs in the stroma of tumour subtypes (B) and
bone marrow of HLH patients (C) Median Fluorescence Intensity of CD33 staining on M-MDSCs and G-MDSCs in the blood of cancer (RED) or HLH (YELLOW) patients (n = 81).
D) Percentage of CD14 + CD33+ M-MDSCs in the blood of cancer patients (RED n = 81) and patients with secondary HLH (YELLOW,n = 7) E) T cell proliferation is suppressed
following culture with CD33+ MDSCs from the blood of patients at diagnosis.
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Fig. 4. Gemtuzumab ozogamicin is cytotoxic to MDSCs. A) ALEXA-647-Gemtuzumab ozogamicin is rapidly internalised into MDSCs over time. Flow cytometric representation of 3
independent experiments. Gemtuzumab ozogamicin speciﬁcally depletes CD33+ MDSCs from the whole blood of patients ex vivo (BLUE), with no effect on the CD33- populations of
cells (RED). Representative dose response curve of cell viability (B) and ﬂow cytometry gating (C) shown D) Gemtuzumab ozogamicin (1 or 2 μg/ml) signiﬁcantly reduces the viability
of CD33+ patient-derived or tumour-polarised MDSCs from different cancer subtypes, as assessed by ﬂow cytometry E) Confocal microscopy of GO-treated (1 μg/ml) CD33+MDSCs
from the blood of patients showing increased p-ATM F) Transmission electron microscopy shows loss of cell membrane integrity, nuclear condensation, and blebbing consistent with
apoptotic cell death after 1 μg/ml GO treatment.
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Fig. 5. Gemtuzumab ozogamicin restores T cell and CAR-T cell proliferation and cytotoxicity. A) Treatment of patient-derived or tumour-polarised MDSCs from different cancer subtypes
with Gemtuzumab ozogamicin restores T cell proliferation in co-culture as assessed by 3H-thymidine incorporation B) Representative ﬂow cytometry gating showing the enhanced
proliferation of CAR-T cells (BLUE) following the depletion of MDSCs by Gemtuzumab ozogamicin in tumour co-cultures C) Gemtuzumab ozogamicin depletion of MDSCs enhances
CAR-T cell proliferation, as assessed by ﬂow cytometry. Anti-mesothelin CART cells, anti-GD2 CART cells, and anti-EGFRvIII CART cells D)Representative ﬂow cytometry gating on
CFSE-labelled H1299M tumour cells in the presence of anti-mesothelin CAR-T cells and CD33 +MDSCs. E) Gemtuzumab ozogamicin depletion of MDSCs enhances CAR-T cell killing of
target tumour cells, as assessed by ﬂow cytometry. Representative of 4 independent experiments.
243L. Fultang et al. / EBioMedicine 47 (2019) 235–246
244 L. Fultang et al. / EBioMedicine 47 (2019) 235–246CD33, Siglec-8, also provide anattractive target for antibody-based ther-
apeutic due to their cell-speciﬁc surface expression and rapid
internalisation kinetics [37–39]. CD33 may be targeted through uncon-
jugated antibodies, however these antibodies are not usually cytotoxic
and do not lead to sustained depletions of the target cells - minimising
any therapeutic beneﬁt [40,41]. Instead immunotoxins, such as
Gemtuzumab ozogamicin, can induce a cell-speciﬁc cytotoxicity alone,
without reliance on Antibody-Dependent Cellular Cytotoxicity. We
show that the end result is a depletion, rather than a modulation, of
the MDSCs, hence removing the immunosuppression regardless of the
mechanism. Although CD33 may also be expressed on normal mono-
cytes and macrophages in healthy individuals, critically it is the
MDSCs which represent the bulk of myeloid-cells in the cancer patients
who would receive Gemtuzumab ozogamicin. Furthermore we show
that GO does not bind the CD33- populations of cells, thus immunity
provided by granulocytes or T cells remains unopposed.T Cell
MDSC
Untreated 1
CD33
Tumour 
Cell growth  
CAR-T Cell
 OR
Cytotoxicity
Proliferation
Fig. 6. Schematic illustrating the capacity ofMDSCs to suppress T cell and CAR-T cell proliferatio
proliferation, leading to enhanced tumour cell death.Myeloid cells also play critical roles in driving the rare but often fatal
conditions of Haemophagocytic Lymphohistiocytosis and Macrophage
Activation Syndrome [10,11]. Recently the diagnosis of HLH/MAS has
become notable due to the use of immunotherapy approaches in cancer
patients treated with Chimeric-Antigen Receptor T cells or antibodies
[42,43]. Although it is recognised that myeloid cells secrete IL-1β or
IL-6, modulate T and NK cells, or directly consume erythrocytes are cen-
tral to the underlyingpathology, no therapies have directlymanipulated
these cells [12]. Instead therapies have centred on multi-drug chemo-
therapies, T cell depletion, or inhibition of Il-1β or IL-6 [44]. As a rare
and non-malignant disease few treatments have been developed
which rationally target the underlying biological mechanisms, contrib-
uting to the poor prognosis for these patients (Supp Fig. 8).
Gemtuzumab ozogamicin has already completed Phase III adult tri-
als and is subject to ongoing paediatric trials in children,with amanage-
able toxicity proﬁle to date [45]. We suggest our ﬁndings have major
clinical implications for the use of Gemtuzumab ozogamicin as anTreated 2
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n and cytotoxicity. Treatment with GemtuzumabOzogamicin restores T cell and CAR-T cell
245L. Fultang et al. / EBioMedicine 47 (2019) 235–246adjunct to chemotherapies and immunotherapies in adult and paediat-
ric solid cancers. It is possible that patients with the highest frequencies
of M-MDSCs, such as those with advanced or relapsed disease, may gain
the most useful clinical effect from GO therapy by turning immunolog-
ically ‘cold’ tumours, into immunologically hot’ ones. Indeed in the con-
text of CAR-T cells, co-treatment of Gemtuzumab ozogamicin could
enhance CAR-T cell persistence and anti-tumour activity which has lim-
ited trial outcomes in solid tumours to date. To this end we will rapidly
translate our preclinical ﬁndings to investigate the activity of
Gemtuzumab Ozogamicin in HAemophagcytic lymphohistiocytosis
(HLH) or Macrophage activation syndrome or relapsed/refractory
solid tumours in an upcoming Phase II clinical trial (GOTHAM).
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.08.025.
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